Patent · US Active

CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease

US9637542B2 · kind B2 · utility

2Cited by

1References

16Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Alisa K. Waterman · Weston, US
Nick Devoogdt · Zemst, BE
Tony Lahoutte · Ganshoren, BE
Matthias Schneider · Dossenheim, DE
Sanjaya Singh · Sandy Hook, US
Cedric Jozef Neotere Ververken · Merelbeke, BE

Key dates

Filing date	Aug 20, 2014
Grant date	May 2, 2017
Priority date	—
Expiry date	Mar 25, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/7158
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.